Company intelligence / Profile preview
Right Brain Bio
Westchester County, New York, United Statesrightbrainbio.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
Right Brain Bio has developed RB-190, a repurposed form of metyrosine, based on the discovery that excess intracellular dopamine causes neurodegeneration in Parkinson’s disease. Preclinical studies in nine models have shown reversal of pathology. The FDA has reviewed the data and confirmed readiness for an IND submission for a Phase 2 trial.
- Therapeutic areas
- Neurology
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Suven Pharmaceuticals (manufacturing partner for RB-190)
Beyond the preview
Go deeper on Right Brain Bio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Right Brain Bio.